Neutralization of SARS-CoV-2 variants B. 1.429 and B. 1.351
New England Journal of Medicine, 2021•Mass Medical Soc
Cross-Reactive Neutralization of SARS-CoV-2 Variants An analysis of cross-reactive viral
binding and neutralization of emerging SARS-CoV-2 variants suggests that the mRNA-1273
and NVX-CoV2373 vaccines elicit immune responses that are effective at neutralizing the B.
1.429 variant but less effective in recognizing the B. 1.351 variant.
binding and neutralization of emerging SARS-CoV-2 variants suggests that the mRNA-1273
and NVX-CoV2373 vaccines elicit immune responses that are effective at neutralizing the B.
1.429 variant but less effective in recognizing the B. 1.351 variant.
Cross-Reactive Neutralization of SARS-CoV-2 Variants
An analysis of cross-reactive viral binding and neutralization of emerging SARS-CoV-2 variants suggests that the mRNA-1273 and NVX-CoV2373 vaccines elicit immune responses that are effective at neutralizing the B.1.429 variant but less effective in recognizing the B.1.351 variant.
The New England Journal Of Medicine以上显示的是最相近的搜索结果。 查看全部搜索结果